Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell Growth through activating protein kinase A (PKA) (Patent pending)
Corresponding Author: Zhenyu Yue, PhD, Professor of Neurology, Aidekman Family Professorship, Director of Basic and Translational Research in Movement Disorders, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
Bottom Line: We uncovered a mechanism that tumor cells exploit selective autophagy for metabolic reprogramming that benefits tumor cell growth and offers resistance to glucose deprivation. Our study suggests that AKAP220-mediated autophagy as a novel therapeutic target for specific cancer treatment.
E-Mail
IMAGE: Hirofumi Morishita, MD, PhD, Associate Professor of Psychiatry, Neuroscience and Opthalmology at the Icahn School of Medicine at Mount Sinai and lead author of the study. view more
Credit: Mount Sinai Health System
Mount Sinai Researchers find a new way to prevent attention deficits associated with Fragile X, a leading genetic cause of autism, in an animal model
Corresponding Author: Hirofumi Morishita, MD, PhD, Department of Psychiatry, Neuroscience, Friedman Brain Institute, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York.
Bottom Line: The adolescent maturation of the frontal cortex is important for establishing cognitive function, and disruption of this process is associated with neurodevelopmental disorders. This study uncovered a new molecular driver of frontal circuit maturation that is essential for cognitive function, and demonstrated, in an animal model, that this mechanism can be targeted to